Avalo Therapeutics Is Worth a Billion Dollars on a Trial It Hasn't Started

Avalo Therapeutics sent out a press release the other day to say it would be appearing at investor conferences. This is the junk mail of biotech: no data, no deal, no milestone, just management booking a fireside chat. And yet the company bothered to announce it. That is the tell. Pre-revenue biotechs with one drug and a long road to market send out conference notices because the calendar of public appearances is the marketing — the way a company with no earnings and no near-term catalyst keeps the story warm in front of the people who set its price. The conference itself is trivial. Knowing why Avalo needs to keep the story warm tells you most of what matters about the company.

The basic point is that Avalo is a single-asset, clinical-stage company whose entire roughly one-billion-dollar market value is now a claim on a phase 3 trial it has not started yet. That is a strange thing to be worth a billion dollars, so let me show you the machine underneath.

One drug, one data point

Avalo is dedicated to drugs targeting a signaling molecule called IL-1β, which drives inflammation, and its lead candidate, abdakibart (AVTX-009), is aimed at hidradenitis suppurativa, a chronic inflammatory skin disease that causes painful lesions and affects an estimated 1% to 4% of the global population. There is no revenue. There are only clinical trials, and there is exactly one data point so far worth hanging a valuation on.

That data point landed in May 2026, when the phase 2 trial, called LOTUS, hit its primary endpoint. Among 253 patients with moderate-to-severe disease, the drug produced a "HiSCR75" response — meaning at least a 75% improvement in inflamed lesions — in 42.2% of patients on the lower dose and 42.9% on the higher dose at week 16, versus 25.6% on placebo. Both doses were statistically significant, and the company called the safety profile favorable. That is a real result. It is also, functionally, an advertisement for the phase 3 trial that comes next: Avalo plans to launch a registrational phase 3 program in the first half of 2027, with a readout years beyond that.

Where the money came from

The more interesting part is how Avalo paid for the claim. In May 2026, in the same week the phase 2 data came out, Avalo completed an underwritten public offering of stock and pre-funded warrants for gross proceeds of $431.3 million, netting roughly $405 million. That matters because of what it did to the share count. The company went from about 18.5 million shares outstanding at the end of 2025 to just under 53 million by the end of June 2026. Avalo finished the second quarter with $472.2 million in cash and investments, enough, it says, to fund operations into 2029.

Read that sequence the way a structure person would: the company raised its big war chest at the exact moment its one de-risking data point made it cheapest to sell shares. That is how a pre-revenue developer of a single drug typically works — sell equity into strength, because there is no cash flow and no other way to fund a trial that will run for years. The consequence of the mechanism is dilution. The company that will own the phase 3 result will be a company with roughly three times as many shares as the one that announced phase 2.

The deal inside the deal

But the strangest piece of plumbing in the whole story is a small negotiation Avalo did in April, right before the offering. Abdakibart was not invented at Avalo; it came from a 2024 acquisition of a company called AlmataBio, and as part of that deal Avalo owed a $15 million milestone payment once the first patient was dosed in a phase 3 trial. Before that day arrived, Avalo paid $2.25 million for an option — exercisable within 90 days — to instead pay $5.125 million, in cash or stock, and wipe out the $15 million milestone entirely.

Investor: We thought you owed the sellers fifteen million. Company: Sure, but we bought an option that lets us settle for a third of it if we want to.

This is basically Avalo negotiating with its own acquisition debt between data points: it spent a little cash to buy certainty about a bigger payment it might not have wanted to make in full. It is exactly the sort of thing you see when a company is being careful about its balance sheet before a big financing — and it says more about how management thinks about capital than any length of fireside chat will.

What a billion dollars is actually paying for

Pull it all together and the picture is clearer than the conference invitations make it seem. Avalo is a company with no revenue, one successful phase 2 readout, a fully funded balance sheet running into 2029, and a roughly $1 billion market cap. The money on the table is almost entirely a bet on a phase 3 program that has not begun — plus a second, more convenient-to-dose follow-up drug, AVTX-010, that Avalo plans to file an investigational-new-drug application for in the first half of 2027. Nothing about that is broken, and the phase 2 data give the bet legs. Clinical stage, though, is clinical stage: the traditional failure rate between an encouraging phase 2 and an approved drug is the reason this kind of stock trades the way it does, and with roughly three times the shares now split across the same single asset, the mistake, if the phase 3 disappoints, gets multiplied across more shareholders — the flip side of the share count that funded the run.

So the next time Avalo announces it will appear at a conference, you can safely file it under "marketing." The date that actually moves the price has already been set, and it is not on the conference schedule. It is the first patient dosed in that phase 3 trial, sometime in the first half of 2027 — the milestone Avalo and its sellers spent the spring negotiating over, and the moment this whole story stops being a promise.